144 related articles for article (PubMed ID: 8222074)
21. Increased expression of cholecystokinin-A receptor mRNA in pancreas and cholecystokinin-B receptor mRNA in oxyntic mucosa after porta-caval shunting in rats.
Nylander AG; von Friesen CP; Monstein HJ; Yamada H; Chen D; Boketoft A; Håkanson R
Pharmacol Toxicol; 1997 Mar; 80(3):147-51. PubMed ID: 9101588
[TBL] [Abstract][Full Text] [Related]
22. Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy.
de Jong M; Bakker WH; Bernard BF; Valkema R; Kwekkeboom DJ; Reubi JC; Srinivasan A; Schmidt M; Krenning EP
J Nucl Med; 1999 Dec; 40(12):2081-7. PubMed ID: 10616889
[TBL] [Abstract][Full Text] [Related]
23. Transient agonist-induced regulation of the cholecystokinin-A and cholecystokinin-B receptor mRNA levels in rat pancreatic acinar AR42J cells.
Günther R; Carstens OC; Schmidt WE; Fölsch UR
Pancreatology; 2003; 3(1):47-54. PubMed ID: 12649564
[TBL] [Abstract][Full Text] [Related]
24. Pancreatic endocrine dysfunction in rats not expressing the cholecystokinin-A receptor.
Funakoshi A; Miyasaka K; Kanai S; Masuda M; Yasunami Y; Nagai T; Ikeda S; Jimi A; Kawanami T; Kono A
Pancreas; 1996 Apr; 12(3):230-6. PubMed ID: 8830328
[TBL] [Abstract][Full Text] [Related]
25. Inhibition by verapamil of cholecystokinin-enhancement of pancreatic carcinogenesis induced by azaserine in Wistar rats.
Nakaizumi A; Uehara H; Baba M; Iishi H; Tatsuta M
Cancer Lett; 1996 Jul; 105(1):23-7. PubMed ID: 8689627
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of cholecystokinin-B/gastrin receptor gene in the stomach of naturally occurring cholecystokinin-A receptor gene knockout rats.
Miyasaka K; Kanai S; Ohta M; Jimi A; Kono A; Funakoshi A
Digestion; 1998; 59(1):26-32. PubMed ID: 9468095
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of cholecystokinin, gastrin, CCK-A receptor, and CCK-B/gastrin receptor gene expressions in gastric cancer.
Okada N; Kubota A; Imamura T; Suwa H; Kawaguchi Y; Ohshio G; Seino Y; Imamura M
Cancer Lett; 1996 Sep; 106(2):257-62. PubMed ID: 8844981
[TBL] [Abstract][Full Text] [Related]
28. The human brain cholecystokinin-B/gastrin receptor. Cloning and characterization.
Lee YM; Beinborn M; McBride EW; Lu M; Kolakowski LF; Kopin AS
J Biol Chem; 1993 Apr; 268(11):8164-9. PubMed ID: 7681836
[TBL] [Abstract][Full Text] [Related]
29. Transforming growth factor-alpha and epidermal growth factor expression in the exocrine pancreas of azaserine-treated rats: modulation by cholecystokinin or a low fat, high fiber (caloric restricted) diet.
Visser CJ; Woutersen RA; Bruggink AH; van Garderen-Hoetmer A; Seifert-Bock I; Tilanus MG; de Weger RA
Carcinogenesis; 1995 Sep; 16(9):2075-82. PubMed ID: 7554057
[TBL] [Abstract][Full Text] [Related]
30. A misspliced form of the cholecystokinin-B/gastrin receptor in pancreatic carcinoma: role of reduced sellular U2AF35 and a suboptimal 3'-splicing site leading to retention of the fourth intron.
Ding WQ; Kuntz SM; Miller LJ
Cancer Res; 2002 Feb; 62(3):947-52. PubMed ID: 11830556
[TBL] [Abstract][Full Text] [Related]
31. Characterization of the CCK-C (cancer) receptor in human pancreatic cancer.
Smith JP; Verderame MF; McLaughlin P; Martenis M; Ballard E; Zagon IS
Int J Mol Med; 2002 Dec; 10(6):689-94. PubMed ID: 12429993
[TBL] [Abstract][Full Text] [Related]
32. Cholecystokinin A and B receptors are differentially expressed in normal pancreas and pancreatic adenocarcinoma.
Weinberg DS; Ruggeri B; Barber MT; Biswas S; Miknyocki S; Waldman SA
J Clin Invest; 1997 Aug; 100(3):597-603. PubMed ID: 9239407
[TBL] [Abstract][Full Text] [Related]
33. Chronic oral administration of protease inhibitor decreases CCK-A receptor mRNA expression but increases pancreatic growth in rats.
Fukumitsu K; Nakamura H; Otsuki M
Pancreas; 2001 Mar; 22(2):179-85. PubMed ID: 11249073
[TBL] [Abstract][Full Text] [Related]
34. Mechanism of cholecystokinin-A- receptor antagonist on human pancreatic exocrine secretion. Localization of CCK-A receptor in the human duodenum.
Funakoshi A; Fukamizu Y; Miyasaka K
Digestion; 1999; 60 Suppl 1():75-80. PubMed ID: 10026437
[TBL] [Abstract][Full Text] [Related]
35. Effects of dietary fats and soybean protein on azaserine-induced pancreatic carcinogenesis and plasma cholecystokinin in the rat.
Roebuck BD; Kaplita PV; Edwards BR; Praissman M
Cancer Res; 1987 Mar; 47(5):1333-8. PubMed ID: 3815341
[TBL] [Abstract][Full Text] [Related]
36. Neoplastic transformation of propagable cultured rat pancreatic duct epithelial cells by azaserine and streptozotocin.
Shepherd JG; Chen JR; Tsao MS; Duguid WP
Carcinogenesis; 1993 May; 14(5):1027-33. PubMed ID: 8099312
[TBL] [Abstract][Full Text] [Related]
37. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies.
Behr TM; Béhé MP
Semin Nucl Med; 2002 Apr; 32(2):97-109. PubMed ID: 11965605
[TBL] [Abstract][Full Text] [Related]
38. Exogenous CCK and gastrin stimulate pancreatic exocrine secretion via CCK-A but also via CCK-B/gastrin receptors in the calf.
Le Dréan G; Le Huërou-Luron I; Gestin M; Desbois C; Romé V; Bernard C; Dufresne M; Moroder L; Gully D; Chayvialle JA; Fourmy D; Guilloteau P
Pflugers Arch; 1999 Jun; 438(1):86-93. PubMed ID: 10370091
[TBL] [Abstract][Full Text] [Related]
39. Effects of cholecystokinin and bombesin on development of azaserine-induced pancreatic tumours in rats: modulation by the cholecystokinin receptor antagonist lorglumide.
Meijers M; Appel MJ; van Garderen-Hoetmer A; Lamers CB; Rovati LC; Jansen JB; Woutersen RA
Carcinogenesis; 1992 Sep; 13(9):1525-8. PubMed ID: 1394835
[TBL] [Abstract][Full Text] [Related]
40. Quantitative analysis of gastrin mRNA and peptide in normal and cancerous human pancreas.
Smith JP; Hamory MW; Verderame MF; Zagon IS
Int J Mol Med; 1998 Sep; 2(3):309-15. PubMed ID: 9855703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
